U.S., Nov. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07945821) titled 'A Study of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors' on Nov. 13.

Brief Summary: The primary purpose of this study is to evaluate the safety and tolerability of tagmokitug in combination with other therapies.

Study Start Date: Nov., 2026

Study Type: INTERVENTIONAL

Condition: Solid Tumor

Intervention: DRUG: Tagmokitug

Specified dose on specified days.

DRUG: Pasritamig

Specified dose on specified days.

Recruitment Status: RECRUITING

Sponsor: Coherus Oncology, Inc.

Published by HT Digital Content Services with permission from Health Daily Digest....